ArticleBMC cancer2025
The role of urinary microbiota in primary and recurrent bladder cancer: insights from a propensity score matching study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Intravesical mycobacteria reshape bladder and gut microbiota in a murine bladder cancer model.NPJ biofilms and microbiomes · 2026Article
- Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies.Molecular biomedicine · 2026Review
- Urinary microbiota diversity and composition in patients with advanced renal cell cancer.BJUI compass · 2026Article
- The emerging role of the microbiome in bladder cancer: prognostic implications and treatment response.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Review
- Mechanisms of microbiome-immune interactions in bladder cancer and targeted regulatory strategies.Frontiers in immunology · 2026Review
- Urinary Microbiota Composition in Treatment-Naïve Bladder Cancer: A Case-Control Study with Tumor Invasiveness Stratification.Medicina (Kaunas, Lithuania) · 2025Article
- Metabolite-mediated mechanisms linking the urinary microbiome to bladder cancer.Journal of microbiology (Seoul, Korea) · 2025Review
- Exploring the Anticancer Potential of the Multistrain Probiotic FormulationAntioxidants (Basel, Switzerland) · 2025Article
- Gut microbiota alterations and systemic inflammation in community-acquired pneumonia: a prospective gut-lung axis study.Frontiers in immunology · 2025Article
- Dynamic changes of urinary microbiota in patients with bladder cancer after surgery and its clinical significance.Frontiers in immunology · 2025Review
- Carcinogen metabolism and bladder cancer: role of gut microbiota in disease and prevention.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBladder cancer (BCa) is a common urinary malignancy with high recurrence rates in non-muscle invasive bladder cancer (NMIBC), posing significant clinical challenges. Emerging evidence links urinary microbiota to cancer progression; however, their role in BCa recurrence remains unclear. This study aimed to explore urinary microbiota differences between primary and recurrent BCa to identify potential microbiological markers and mechanisms associated with recurrence.
methodsUrine samples were collected from 170 BCa patients, including 125 with primary Bca(BCa_P) and 45 with recurrent BCa (BCa_R). All samples underwent 16 S rRNA gene sequencing, and clinical data were collected, including age, sex, body mass index (BMI), smoking history, pathological grade, and other biological characteristics. Propensity score matching (1:1 ratio, caliper = 0.02) minimized baseline differences, resulting in 39 matched pairs. Microbial diversity was analyzed using α and β diversity indices. Differential taxa were identified with Linear Discriminant Analysis Effect Size (LEfSe), and functional pathways were predicted using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt).
resultsAlpha diversity was significantly higher in BCa_P than BCa_R, particularly in Chao1 indices. β diversity revealed distinct microbial structures (ADONIS, P = 0.004, R² = 0.025). At the phylum level, both BCa_P and BCa_R were dominated by Firmicutes, Proteobacteria, Bacteroidetes, and Actinobacteria, with Firmicutes significantly higher and Bacteroidetes lower in BCa_R. At the genus level, BCa_P was enriched in Sphingomonas, Corynebacterium, Capnocytophaga, Massilia, and Aquabacterium, while BCa_R showed higher levels of Aeromonas, Cupriavidus, and Bradyrhizobium. Functional predictions revealed glucose metabolism and oxidative stress pathways enriched in BCa_R, while pollutant degradation and TCA cycle pathways were prominent in BCa_P.
conclusionThese findings reveal significant differences in urinary microbiota compositions and functional profiles between primary and recurrent BCa patients, with recurrent cases exhibiting reduced microbial diversity and enrichment of potentially pathogenic communities, highlighting their potential roles in tumor progression and recurrence.
trial registrationRegistered with the Chinese Clinical Trial Registry (ChiCTR2300070969) on April 27, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.